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Abstract
As hypoxia-inducible factor stabilizers (HIFs) can artificially enhance an athlete's
erythropoiesis, the World Anti-Doping Agency prohibits their use at all times. Every
urine sample for doping control analysis has to be evaluated for the presence of HIFs
and therefore sensitive methods that allow high sample throughput are needed. Sam-
ples suspicious for the presence of HIFs need to be confirmed following the identifi-
cation criteria established by the World Anti-Doping Agency. Previous work has
shown the advantages of using turbulent flow online solid-phase extraction (SPE)
procedures to reduce matrix effects and retention time shifts. Furthermore, the use
of online SPE allows for automation and high sample throughput. Both an initial test-
ing procedure (ITP) and a confirmation method were developed and validated, using
online SPE liquid chromatography–tandem mass spectrometry (LC–MS/MS), with
limits of detection between 0.1 ng/ml (or possibly lower) and 4 ng/ml (or higher for
GSK360a) and limits of identification between 0.1 ng/ml (or possibly lower) and 1.17
ng/ml. The ITP only takes 6.5 min per sample. To the best of our knowledge, these
are the first ITP and confirmation methods that include more than three HIFs without
the need for manual sample preparation.
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1 | INTRODUCTION
Hypoxia-inducible factor-1 (HIF-1) appears to be the major regulator
of O2 sensing and homeostasis in the human body. The use of
hypoxia-inducible factor stabilizers (HIFs) is believed to provide an
alternative method for the treatment of anemia and other ischemia-
related diseases. HIF-1 is a heterodimer that consists of an α-subunit,
which is the regulatory subunit, and a β-subunit. The activity of the
α-subunit within the cell presents an oxygen-sensitive pattern. Under
normal oxygen conditions, HIF-α is rapidly degraded whereas under
hypoxic conditions this degradation is inhibited, which results in dimer-
ization with HIF-β. This complex will bind to the hypoxia-responsive
element sequences of target gene promoters and will activate genes
involved in hypoxic responses, for example erythropoietin secretion
(Gupta & Wish, 2017; Singh, Wilson, Scho, & Chen, 2020; Sousa Fialho,
Abd Jamil, Stannard, & Heather, 2019; Zhao & Wu, 2013). Buisson
et al., 2016; Eichner et al., 2017; Hansson et al., 2017). Therefore, they
are prohibited by the World Anti-Doping Agency (WADA), both in and
out of competition (TheWorld Anti-Doping Agency, 2020).
The importance of screening for HIFs, in the frame of sports dop-
ing, was described for the first time by Beuck, Schänzer, &
Thevis (2012). Since the addition of HIFs to the Prohibited List, six
adverse analytical findings for this type of substance have been
reported. Four samples were reported for the presence of roxadustat
(FG4592) in 2015 (The World Anti-Doping Agency, 2015a). The inves-
tigation of a positive case for roxadustat was described by Buisson
et al. (2016). Its metabolism was also described (Hansson et al., 2017).
Two molidustat findings were reported in 2017 (The World
Anti-Doping Agency, 2017), for which the detection of the phase II
metabolite was described by Dib et al. (2017).
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Although adverse analytical findings for HIFs have been
reported, most of the HIFs are still in clinical trials. Bay 87-2243 (HIF
inhibitor) is in phase I clinical trials, IOX3 (FG2216) and molidustat
are in phase II clinical trials and daprodustat (GSK1278863A),
roxadustat (FG4592) and vadadustat are in phase III clinical trials.
Owing to adverse effects in clinical trial phase II, IOX3 was replaced
by roxadustat, which is structurally related to IOX3 (Gupta &
Wish, 2017; Singh et al., 2020; Sousa Fialho, Abd Jamil, Stannard, &
Heather, 2019; Yeh et al., 2017). GSK360a is in the pre-clinical phase
(Beuck et al., 2012; Sousa Fialho et al., 2019). Roxadustat has been
approved in China and is under review in Japan for the treatment of
anemia in patients with dialysis-dependent chronic kidney disease
(Dhillon, 2019).
Every urine sample has to be screened for the presence of HIFs
by an initial testing procedure (ITP). Therefore, a method with high
sample throughput is needed. Another requisite is that the method
should be capable of detecting the HIFs at least at the required detec-
tion level of 2 ng/ml set by WADA (The World Anti-Doping
Agency, 2019). Afterwards, the presence of a HIF stabilizer has to be
confirmed via a separate confirmation procedure following the identi-
fication criteria established by WADA (The World Anti-Doping
Agency, 2015b).
Multiple liquid chromatography–mass spectrometry (LC–MS)
methods have been described in the field of doping analysis for
various classes of compounds (Abushareeda et al., 2018; F. Badoud
et al., 2009; Concheiro, Castaneto, Kronstrand, & Huestis, 2015;
Deventer, Pozo, Van Eenoo, & Delbeke, 2009; Deventer, Pozo,
Verstraete, & Van Eenoo, 2014; Görgens et al., 2016; Guddat
et al., 2011; Jiménez Girón, Deventer, Roels, & Van Eenoo, 2012; Kim
et al., 2018; Mazzarino, Fiacco, de la Torre, & Botrè, 2011; O'Byrne,
Kavanagh, Mcnamara, & Stokes, 2013; Sardela et al., 2018). Previous
research has shown that the use of an online trapping strategy can
reduce matrix effects and retention time shifts, which makes it feasi-
ble to achieve low detection limits and compliance with identification
criteria with the use of a minimal amount of urine (<100 μl) (De Wilde,
Roels, Polet, Van Eenoo, & Deventer, 2018; De Wilde, Roels, Van
Eenoo, & Deventer, 2020; Görgens et al., 2016; Pan, Zhang, Zhang, &
Li, 2014). This online trapping strategy has already been used for the
detection of HIFs by the group of Görgens et al. (2016). Our group
showed that, by applying a turbulent flow rate in the loading step
combined with the online solid-phase extraction (SPE), the reduction
of matrix effects is bigger compared with using a normal flow rate
(De Wilde et al., 2018).
Another advantage of using online SPE is the very limited sample
preparation as it is a dilute-and-shoot type of method, which saves
time, money and workload. Additionally, it allows for a high through-
put of samples and automated analysis (Flavia Badoud et al., 2011;
Helfer, Michely, Weber, Meyer, & Maurer, 2017; Nicoli et al., 2016;
Pan et al., 2014).
This study aimed to develop and validate an ITP and confirmation
method for HIFs using turbulent flow online SPE LC–MS/MS, compli-
ant with WADA's minimum required performance limits (MRPL) and
identification criteria (The World Anti-Doping Agency, 2015b, 2019).
2 | EXPERIMENTAL
2.1 | Chemicals and reagents
Water and methanol (MeOH) were purchased from J. T. Baker
(Deventer, The Netherlands). Formic acid (HCOOH) was obtained
from Fisher Scientific (Geel, Belgium). Ammonium formate
(NH4OOCH) was bought from Fisher Scientific (Loughborough,
Leicestershire, UK).
Bay 87-2243 was bought from Selleckchem (Munich, Germany).
Daprodustat (GSK1278863A) and GSK2391220a were a gift from
WADA. GSK360a and vadadustat (AKB-6548) were bought fromTRC
(Toronto, Canada). IOX3 (FG2216) and roxadustat (FG4592) were
purchased from MedChem Express (Sollentuna, Sweden). Molidustat
glucuronide (Bay 1163348) and mefruside were bought from Bayer
HealthCare (Machelen, Belgium). β-Bromo-phenetylamine was
obtained from Sigma-Aldrich (Bornem, Belgium).
2.2 | Instruments
The methods were validated on a Dionex Ultimate 3000, with a
heated column compartment thermostated at 30C, connected to a
TSQ Altis (Thermo Fisher Scientific). The online SPE column was an
Oasis® HLB (2.1× 20 mm, 25 μm) from Waters and the analytical
column was a Zorbax RX C8 (150 × 2 mm, 5 μm) from Agilent
Technologies. A valve-switching system with two six-port valves
was used to switch between the different steps in the analysis. A
tee piece combined the flows of the loading and analytical pump.
The valve switching system is described elsewhere (De Wilde
et al., 2018).
The mobile phases of the loading pump consisted of (A) water
and (B) methanol. The mobile phases of the analytical pump consisted
of (A) water and (B) methanol both containing 0.001% HCOOH/1mM
NH4OOCH. The gradients of the loading and the analytical pump are
described in previous work for the confirmation method (De Wilde
et al., 2020) and are presented in Table 1 (ITP) and Table 2 (confirma-
tion method).
HIFs were detected by electrospray ionization in the selective
reaction mode. The capillary temperature was set to 350C. Sheath
gas pressure, auxiliary gas pressure and ion sweep gas pressure
were set to 40, 0 and 0 arbitrary units, respectively. Spray voltage
for both positive and negative polarity was 3,500 V. Collision gas
pressure was set to 1.5 mTorr. Transitions, collision energies,
RF-values and retention times for every compound are presented in
Table 3. The molecular structures of the investigated HIFs are
depicted in Figure 1.
2.3 | Sample preparation
The sample preparation steps were the same for both methods,
except for the internal standard (mefruside for the ITP,
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β-bromophenetylamine for the confirmation). A 30 μl aliquot of inter-
nal standard solution (100 μg/ml in MeOH) was added to an aliquot of
300 μl of urine. The sample was then centrifuged (5 min, 5,000g) and
100 μl of sample was injected into the system.
2.4 | Validation
For the validation of the ITP, 10 blank human urine samples (pH range
4.7–7.3; specific gravity range 1.007–1.030) were analyzed to check
TABLE 1 Gradients of the loading and the analytical pump for the initial testing procedure (ITP)
Time (min) Flow (ml/min)
Loading pump
Flow (ml/min)
Analytical pump Valve positions
%A %B %A %B Left Right
0 3 100 0 0.4 100 0 1–6 1–6
0.5 3 100 0
1 0.2 100 0
1.1 1–2 1–2
1.8 1–2 1–6
1.9 0.2 100 0 0.4 100 0
2 3 0 100 0.3 100 0
2.1 0.3 10 90
2.9 1–6 1–6
4 3 0 100
4.1 0.3 0 100
4.5 0.3 0 100
4.6 0.3 100 0 0.3 0 100
5.5 0.3 100 0
5.9 3 100 0
6.1 0.3 0 100
6.3 0.4 100 0
6.5 3 100 0 0.4 100 0
TABLE 2 Gradients of the loading and the analytical pump for the confirmation method
Time (min) Flow (ml/min)
Loading pump
Flow (ml/min)
Analytical pump Valve positions
%A %B %A %B Left Right
0 3 100 0 0.4 100 0 1–6 1–6
2 3 100 0
2.5 0.05 100 0
3.5 1–2 1–2
5.9 1–2 1–6
6 0.05 100 0 0.4 100 0
6.1 3 0 100 0.3 100 0
7 3 0 100 0.3 45 55 1–6 1–6
7.2 0.3 0 100
13 0.3 10 90
13.5 0.3 0 100
13.9 0.3 0 100
14 0.3 100 0
14.5 0.3 0 100
14.7 0.4 100 0
14.8 3 100 0
16.5 3 100 0 0.4 100 0
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TABLE 3 Polarity, transitions for ITP and confirmation, collision energies, RF-values and retention times (tR) for every compound. NV: not
validated
Compound
Ionization
mode
Transition for ITP
Transitions for
confirmation
Collision
energy RF-value
t R for ITP
(min)
t R for
confirmation
(min)Parent Product Parent Product
Bay 87-2243 + 526.35 443.21 526.35 241.14 32 106 5.92 ± 0.01 14.78 ± 0.03
443.21a 24
β-Bromo-phenetylamine
(IS)
+ NV NV 200.00 104.05 24 54 NV 9.90 ± 0.05
Daprodustat + 291.21 394.21 230.13 20 52 5.59 ± 0.02 14.27 ± 0.08
− 392.20 392.20 291.21a 19 57
GSK2391220a − 424.20 323.21 424.20 138.16 40 73 4.62 ± 0.02 10.18 ± 0.05
323.21a 19
GSK360a + 349.21 274.13 349.21 150.05 35 62 5.15 ± 0.01 12.60 ± 0.11
274.13a 14
IOX3 − 279.05 178.04 279.05 178.04 22 52 4.98 ± 0.03 11.26 ± 0.01
+ 281.08 206.04a 19 54
Roxadustat + 353.11 278.13 353.11 249.84 26 66 5.23 ± 0.02 12.86 ± 0.10
278.13a 18
Mefruside (IS) + 383.17 284.97 NV NV 18 68 4.73 ± 0.01 NV
− 381.20 345.13 21 102
Molidustat glucuronide + 491.16 260.14 491.16 207.13 48 70 4.19 ± 0.04 9.00 ± 0.02
260.14a 33
Vadadustat + 307.12 232.04 307.12 203.97 25 60 5.00 ± 0.02 11.67 ± 0.01
232.04a 19
aMost abundant ion.
F IGURE 1 Molecular structures of
the investigated HIFs
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for matrix interferences. The same samples were spiked by two
different analysts at the MRPL, which is 2 ng/ml for HIFs (The World
Anti-Doping Agency, 2019), to check the MRPL compliance. For the
validation of the confirmation method, 10 blank human urine samples
(pH range 4.7–7.3; specific gravity range 1.005–1.024) were analyzed
to check for matrix interferences. The same samples were spiked by
two different analysts at MRPL to check the MRPL compliance.
Diagnostic ions were found and retention times and ratios of diagnos-
tic ions were checked for compliance with WADA's identification
criteria (The World Anti-Doping Agency, 2015b).
2.4.1 | Limit of detection
To estimate the limit of detection (LOD) and the lower limit of detec-
tion (LLOD), 10 blank urine samples were spiked at six different levels
(2MRPL, MRPL, 0.75MRPL, 0.5MRPL, 0.25MRPL and 0.1MRPL). The
LOD was estimated by making a score chart through plotting the
detection rate in the 10 spiked urine samples vs. their concentration.
An intersection was made between the 95% detection rate probability
and the fitted sigmoid curve. Hence, the LOD was defined as the
concentration level with a 95% detection probability. The LLOD was
determined as the lowest concentration of those six levels at which
the compound was still present with a signal-to-noise ratio >3 in any
of the samples.
2.4.2 | Limit of identification
For a confirmation procedure, it is important to know the level at
which the presence of a substance can be confirmed according to
WADA's chromatographic and mass spectrometric identification
criteria (The World Anti-Doping Agency, 2015b). Hence, for confirma-
tion methods, a limit of identification (LOI), rather than an LOD, is
determined and defined as the lowest level at which the identification
criteria are met. To establish the LOI, 10 urine samples were spiked at
the same levels as for the determination of the LOD. As for the LOD,
a sigmoid curve was used as a model (plotting the rate of identifica-
tion in the 10 samples vs. concentration) to estimate the LOI, i.e. the
concentration with a 95% probability of matching the WADA techni-
cal document on identification criteria (TDIDCR) requirements (The
World Anti-Doping Agency, 2015b).
2.4.3 | Matrix effect
Two types of matrix effects were evaluated, the first one being ion
suppression/enhancement. The average of peak areas of the spiked
urine samples was compared with the average area in a spiked water
sample, analyzed at the beginning and the end of each batch. The
formula used to calculate the matrix effect was: matrix effect (%) =
(urine/water area ratio) × 100 − 100 (Matuszewski, Constanzer, &
Chavez-Eng, 2003). The second type of matrix effect was retention
time stability. The average retention times in the urine samples were
compared with the average retention time in the spiked water sample
analyzed at the beginning and the end of each batch.
2.4.4 | Carryover
A disadvantage of online SPE is the possible carryover (Asakawa,
Ozawa, Osada, Kaneko, & Asakawa, 2007; De Wilde et al., 2018,
2020; Helfer et al., 2017; Kousoulos, Dotsikas, & Loukas, 2007;
Segura, Gagnon, & Sauvé, 2007; Viglino, Aboulfadl, Mahvelat,
Prévost, & Sauvé, 2008). Carryover is especially important in ITP
methods and has to be taken into account. A negative control urine
sample was spiked at 4 ×MRPL (8 ng/ml) after which a negative urine
sample was analyzed three times. The area of the peak in the blank
urine sample was compared with the area of the peak in the spiked
urine sample.
2.5 | Application to blind proficiency test samples
Three blind proficiency test samples (samples a, b and c), provided by
WADA, were analyzed with the developed ITP and the confirmation
method. In these samples, the presence of GSK2391220a, roxadustat
and molidustat glucuronide was expected, respectively. With every
batch of samples in the ITP, a system blank sample (water), a negative
control urine (NU) sample and a positive control (QC) sample, spiked
at MRPL, were analyzed as well. In the confirmation procedure, a sys-
tem blank, negative control urine and a QC sample, spiked at MRPL,
were analyzed together with the sample that had to be confirmed.
3 | RESULTS AND DISCUSSION
3.1 | Method development
To optimize transitions for all compounds, infusion experiments were
performed in positive and negative ionization mode, after which the
most abundant ions were selected. Similar fragment ions were
observed for roxadustat to those of Hansson et al. (2017), Buisson
et al. (2016) and Eichner et al. (2017) and for molidustat glucuronide
to those of Dib et al. (2017). Next to the HIF stabilizers, one HIF
inhibitor (Bay 87-2243) was included as it is sometimes unduly cate-
gorized as an HIF stabilizer.
During method development, two peaks were observed for
roxadustat. The work of Hansson et al. (2017) confirmed this finding
and attributed this peak to a degradation product of roxadustat. After
the injection of molidustat (Bay 85-3934), bad peak shapes were
obtained which deteriorated with the lifetime of the column. As this
is not compatible with an ITP procedure and the group of Dib
et al. (2017) stated that the unmodified molidustat is not expected to
be excreted into urine in adequate amounts, the focus was put on its
phase II metabolite.
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As the application of turbulent flow online SPE LC–MS/MS has
already proven to be successful for the confirmation of diuretics and
masking agents (De Wilde et al., 2018) and stimulants (De Wilde
et al., 2020), the same methodology was applied to develop a method
for the confirmation of HIFs. Hence, the same mobile phases,
columns, loading gradient and analytical gradient were used. The only
difference from the previous methods for diuretics and stimulants is
that HIFs have to be detected at a factor of 50 times lower.
Therefore, instead of 20 μl of sample, 100 μl of sample was injected
into the system to achieve the required sensitivity.
This developed confirmation method became the basis of
the development of an ITP method. The ITP had to be shorter than
the confirmation method to obtain high sample throughput. Also, the
same columns and mobile phases were utilized, which allowed harmo-
nization and the same configuration of the instrument to be kept.
To shorten the confirmation method, initially, the loading of
the compounds had to be checked. The loading step was decreased
from 2 to 0.5min. Subsequently, the transfer flow rate was
optimized. It is important to evaluate the peak shapes of the
compounds when increasing the transfer flow rate because the
ratio of the transfer flow rate and the analytical flow rate is impor-
tant for focusing the compounds at the head of the analytical col-
umn (De Wilde et al., 2018; Herman, 2005). As the flow rate could
be increased up to 0.2ml/min without influencing the peak shape
of the compounds, the transfer time could be decreased. A steeper
and shorter analytical gradient could be applied to separate the
included HIFs. A comparison between the two methods is shown
in Figure 2.
3.2 | Validation
The estimated LODs are tabulated in Table 4 and were <50% of the
MRPL for every compound, which is a requirement of The World
Anti-Doping Agency (2019), except for GSK360a and vadadustat.
High background levels were noticed at the retention times of
vadadustat and GSK360a in the ITP method, which explains the
higher LOD for these compounds. As the confirmation method had a
longer gradient, the background was separated from the two com-
pounds. The ITP was focussed on the HIFs which are already available
on the market and additional HIFs were monitored. If the other HIFs
becaome available on the market, a switch can be made to an ITP with
a longer chromatographic run to meet the WADA criteria for these
compounds as well. Figure 3 presents the sigmoid curve which was
used to estimate the LOD for molidustat glucuronide. The 95%
F IGURE 2 Comparison between the confirmation method and
the ITP
TABLE 4 Limit of detection (LOD), limit of identification (LOI) and matrix effects for the ITP and the confirmation method
Compound LOD (ng/ml) LOI (ng/ml)
Matrix effect
ITP (%) tR shift ITP (min)
Matrix effect
confirmation (%) tR shift confirmation (min)
Bay 87-2243 ≤0.10 0.77 +104 ± 260 0.01 ± 0.01 −72 ± 17 −0.01 ± 0.01
Daprodustat ≤0.10 ≤0.10 +342 ± 475 0.00 ± 0.02 −34 ± 38 −0.01 ± 0.02
GSK2391220a ≤0.10 0.95 −48 ± 22 0.02 ± 0.02 −55 ± 15 −0.06 ± 0.04
GSK360a >4* 0.33 −20 ± 59 0.01 ± 0.01 −60 ± 19 −0.02 ± 0.02
IOX3 0.97 1.28 −33 ± 22 0.03 ± 0.03 +3 ± 50 −0.01 ± 0.01
Roxadustat 0.22 ≤0.10 −15 ± 70 0.02 ± 0.02 −62 ± 15 −0.04 ± 0.02
Molidustat glucuronide 0.97 1.09 −72 ± 19 −0.05 ± 0.04 −72 ± 17 −0.07 ± 0.06
Vadadustat 1.85 1.17 −15 ± 53 0.01 ± 0.03 +250 ± 149 −0.01 ± 0.01
*GSK360a was detected in 50 and 70% of the samples at MRPL and 2MRPL, respectively.
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detection rate curve intersects the fitted sigmoid curve at 48.63% of
the MRPL, which corresponds to 0.97 ng/ml. As no level below
0.1MRPL was tested, the LLOD was estimated as ≤0.2 ng/ml for
every compound (except for GSK360a, i.e. 0.5 ng/ml). This shows that,
while in some samples the WADA criteria could not be met, GSK360a
can be detected at or even below the MRPL.
F IGURE 3 Sigmoid curve to determine the
LOD for molidustat glucuronide. The orange
squares show the detection rate at different
concentration levels. The black solid line
represents the fitted sigmoid curve. The dashed
line represents the 95 % detection rate
F IGURE 4 ITP results of the blind proficiency test samples. NU: negative control sample; QC: positive control sample. The QC's were spiked
at 2 ng/ml
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For the confirmation method, the validation results showed that
the presence of HIFs could be confirmed according to WADA's
TDIDCR requirements in urine with LOIs varying between 0.1
(or possibly lower) and 1.17 ng/ml (Table 4).
The matrix effects for both ITP and confirmation methods are
presented inTable 4. Both ion suppression and ion enhancement were
observed. The group of Eichner et al. also observed ion suppression
for roxadustat in their ITP (dilute-and-inject). However, they observed
ion enhancement in their confirmation procedure, which is based on
offline SPE with an Oasis HLB cartridge (Eichner et al., 2017). The
group of Dib et al. also observed ion suppression for molidustat glucu-
ronide (11–78%) with their dilute-and-inject method (Dib et al., 2017).
Even though for some compounds the matrix effect was quite high
and there was a lot of variation in matrix effects among samples, all
compounds could be validated at MRPL (The World Anti-Doping
Agency, 2019), except for GSK360a in the ITP. As a lot of background
eluted together with GSK360a, it could only be detected in 50% of
the samples at MRPL and in 70% of the samples at 2MRPL. For the
ITP, carryover was the highest for daprodustat (5.83%). This carryover
has to be taken into account when looking at the ITP results.
WADA's identification criteria were met for every compound in
the confirmation method, at least at MRPL (The World Anti-Doping
Agency, 2015b). For the confirmation, carryover was the highest for
molidustat glucuronide (14.6%). Precautionary measures are taken in
every confirmation procedure to avoid carryover. First of all, only one
sample is confirmed at a time. Secondly, the concentration of the
compound detected in the ITP is compared with the concentration of
the QC (spiked at MRPL) in the ITP. The sample will then be diluted to
approximate the concentration of the QC. Thirdly, analysis of the sus-
picious sample is preceded by the analysis of a system blank and neg-
ative control urine, and followed by the analysis of two solvent blank
injections, negative control urine and the QC.
3.3 | Application to blind proficiency test samples
The ITP results of the three blind proficiency test samples are presented
in Figure 4, together with the results of the NU and the QC, spiked at
MRPL. In sample a, GSK2391220a was detected. Sample b contained
roxadustat and molidustat glucuronide was found in sample c.
F IGURE 5 Confirmation results of the blind proficiency test samples. The samples are presented together with their corresponding positive
control samples (QC's) (2 ng/ml)
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The same samples were analyzed with the developed confirma-
tion method (Figure 5). WADA's identification criteria were met in
every sample. In sample a, the presence of GSK2391220a could be
confirmed. Sample b was confirmed for the presence of roxadustat
and the identification criteria were met for molidustat glucuronide in
sample c.
4 | CONCLUSION
An ITP and confirmation method for HIFs using turbulent flow online
SPE LC–MS/MS were developed and validated following WADA's
criteria. The criterion for the LOD in the ITP method (<50% of the
MRPL) was met for six out of the eight studied compounds. By using
online SPE technology, sample preparation time and workload were
reduced, allowing automation of the sample analysis. A sample can be
screened for the presence of HIFs in only 6.5 min. The ITP results of
the blind proficiency test samples show that every compound could
be detected in every sample. For several compounds, high background
was observed, which limits the sensitivity of the method. However,
the presence of the HIFs in these samples could be confirmed, compli-
ant with WADA's identification criteria. To the best of our knowledge,
these are the first ITP and confirmation methods to include more than
three HIFs without the need for manual sample preparation.
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